Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q2 2019 Earnings Conference Call - Final Transcript
Aug 13, 2019 • 08:00 am ET
Good day, and welcome to BrainStorm Cell Therapeutics Second Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, this call is being recorded. I would now like to introduce your host for today's conference, Sean Leous from ICR Westwicke. Thank you. You may begin.
Thank you for joining the BrainStorm Cell Therapeutics second quarter financial results conference call. Before we begin opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics Inc., Nasdaq BCLI, and its potential future business operations and performance. Statements regarding the market potential for treatment of our neurodegenerative disorders such as ALS and MS, the sufficiency of our existing capital resources for continuing operations in 2019 and beyond, the safety and clinical effectiveness of our NurOwn technology platform, our clinical trials of NurOwn and related clinical development programs, and our ability to develop strategic collaborations and partnerships to support our business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties which -- many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ material from those projected here on today's call. We undertake no obligation to publicly update any forward-looking statements.
Joining me on the call today will be Chaim Lebovits, President and CEO of BrainStorm; Dr. Ralph Kern, Chief Operating and Chief Medical Officer; and Eyal Rubin, our Chief Financial Officer. We will be available to answer your questions during the Q&A session.
Thank you very much, Sean. Good morning and good afternoon to everyone on the second quarter earnings call. Let me begin by thanking everyone for participating in today's call and for all of those that sent their questions prior to our call. We will address many of your pre-submitted questions in the opening remarks. I will look forward to addressing any additional questions or comments you may have in the Q&A session.
On behalf of management, I want to express our thanks for the ongoing and continued support of so many. Firstly, I would like to thank patients, their families, caregivers, and all those who are helping us advance the Phase 3 ALS and Phase 2 progressive MS studies. The dedicated clinical professionals at all our investigational sites continued to provide top tier patient care and the highest quality clinical trial expertise. I also want to thank our wonderful team here at BrainStorm, who fully devoted themselves to advancing best in class and potentially life altering therapies. And finally I want to thank our shareholders, both new and long-term for their continued ongoing support and our collective journey to FDA approval. Many of you have asked about the progress of our Phase 3 ALS trial, which I'm happy to say is nearing the end of patient recruitment.
Today, we have enrolled a total of 170 patients, 85% enrollment. Based on our current projection, we plan to